Correction: CAR T cell therapy for central nervous system solid tumors: current progress and future directions
Year: 2025
Type: erratum
Abstract: A correction refers to a change to their article that the author wishes to publish after publication. The publication of this article is subject to Frontiers' editorial approval. Instructions: ● Please read through all the templates before choosing ● Pick the most relevant text template(s) from the following page and delete all others. ● Edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. ● Please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary ● Submit to Frontiers following the instructions on this page. When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. For example: There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake. The original version of this article has been updated. In the published article, there was a mistake in the Funding statement. The funding statement for the Key Development Project of the Department of Science and Technology was displayed as "2015CBd051". The correct statement is "Key Development Project of Department of Science and Technology (2015C03Bd051).'' Kaminskiy et al. Frontiers Media SA * Correspondence: [email protected] Correction on: CAR T Cell Therapy for Central Nervous System Solid Tumors: Current Progress and Future Directions. Error in table Wrong content There was a mistake in table 1 as published. [CAR T cells in blood; CD3+ T cells correlated with enhanced survival after therapy; ICV beneficial for multifocal tumors and IT beneficial for unifocal tumors; 75% transduction efficiency; IFN-γ, CXCL9 and CXCL10 increase in CNS; Best OS in dual IT/ICV delivery and CD62+ Tn/mem enrichment trial arm;]. The corrected text appears below. [75% transduction efficiency; CAR T cells in blood; CD3+ T cells correlated with enhanced survival after therapy; ICV beneficial for multifocal tumors and IT beneficial for unifocal tumors; IFN-γ, CXCL9 and CXCL10 increase in CNS; Best OS in dual IT/ICV delivery and CD62+ Tn/mem enrichment trial arm] There was a mistake in table 1 as published. [severe hypoxia at highest dose (without IL-2) likely due to congestion of pulmonary vasculature; 66% transduction efficiency]. The corrected text appears below. [66% transduction efficiency; severe hypoxia at highest dose (without IL-2) likely due to congestion of pulmonary vasculature] There was a mistake in table 1 as published. [antigen loss or decrease (potentially attributable to chemotherapy); 9/10 SD after 28 days; CAR T cell expansion; CAR T tumor infiltration; 20% transduction efficiency; IDO1, PD-L1, IL-10 upregulation post therapy;]. The corrected text appears below. [20% transduction efficiency; antigen loss or decrease (potentially attributable to chemotherapy); 9/10 SD after 28 days; CAR T cell expansion; CAR T tumor infiltration; IDO1, PD-L1, IL-10 upregulation post therapy] There was a mistake in table 1 as published. [3/5 SD tumor necrosis; all (3) patients without C7R progressed after 1st infusion; longer PFS in C7R group; CAR T cell expansion and persistence in group with and without C7R; intratumor C7R transgene and residual GD2 detected in one patient analyzed; grade 4 CRS in one patient;]. The corrected text appears below. [3/5 SD tumor necrosis; all patients without C7R progressed after 1st infusion; longer PFS in C7R group; CAR T cell expansion and persistence in group with and without C7R; intratumor C7R transgene and residual GD2 detected in one patient analyzed; grade 4 CRS in one patient] There was a mistake in table 1 as published. [no antigen loss; in vivo CAR T cell expansion; CAR T tumor infiltration in PD case after IV dose; regression of spinal cord tumor but not metastasis after IV dose; Tregs and MDSCs increase post therapy; dose limiting toxicity for IV but not ICV; manageable TIAN in all patients after ICV infusion correlated with CCL2 upregulation; PD associated with TGF-b upregulation; 57% transduction efficiency]. The corrected text appears below. [57% transduction efficiency; no antigen loss; in vivo CAR T cell expansion; CAR T tumor infiltration in PD case after IV dose; regression of spinal cord tumor but not metastasis after IV dose; Tregs and MDSCs increase post therapy; dose limiting toxicity for IV but not ICV; manageable TIAN in all patients after ICV infusion correlated with CCL2 upregulation; PD associated with TGF-b upregulation] There was a mistake in table 1 as published. [8.1 vs 5.4 months PFS against chemotherapy alone;]. The corrected text appears below. [8.1 vs 5.4 months PFS against chemotherapy alone] There was a mistake in table 1 as published. [17.5 vs 13.6 months OS against standard of therapy;]. The corrected text appears below. [17.5 vs 13.6 months OS against standard of therapy] There was a mistake in table 1 as published. [IL-2-related CNS toxicity at 2.4 MIU dose; eosinophils infiltration;]. The corrected text appears below. [IL-2-related CNS toxicity at 2.4 MIU dose; eosinophils infiltration]
Source: Frontiers in Immunology
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: CAR T-cell therapy, intracerebroventricular administration, intrathecal drug delivery, transduction efficiency, interferon-gamma, CXCL9, CXCL10, tumor-infiltrating lymphocytes, hypoxia, interleukin-2, tumor microenvironment, survival outcomes, funding statement correction, table correction
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W4414435313
